Key Points
- Stabilize ABCs; treat life‑threatening derangements immediately.
- Confirm diagnosis early with highest‑yield imaging/labs.
- Initiate guideline‑based therapy and escalate by response.
- Plan disposition and follow‑up explicitly.
Clinical Synopsis & Reasoning
ASUC requires hospitalization, IV steroids (e.g., methylprednisolone 60 mg daily), early flexible sigmoidoscopy, and VTE prophylaxis. Use day‑3 response to decide on rescue therapy (infliximab or cyclosporine). Failure or complications such as toxic megacolon or perforation mandate urgent surgical consultation for subtotal colectomy.
Treatment Strategy & Disposition
ASUC requires hospitalization, IV steroids (e.g., methylprednisolone 60 mg daily), early flexible sigmoidoscopy, and VTE prophylaxis. Use day‑3 response to decide on rescue therapy (infliximab or cyclosporine). Failure or complications such as toxic megacolon or perforation mandate urgent surgical consultation for subtotal colectomy.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitating factors
Initial Targets
Parameter | Target/Action |
Hemodynamics | Maintain perfusion; avoid hypotension |
Monitoring | Serial exam, labs, and imaging |
Therapy | Start early, reassess, de‑escalate when appropriate |
Investigations
Test | Role / Rationale | Typical Findings | Notes |
CBC | Screen leukocytosis/anemia | Context‑specific | Trend response |
BMP | Electrolytes/renal function | Derangements common | Replace K+/Mg2+ |
Key imaging | Condition‑specific (CTA/MRI/Endoscopy) | See text | Do not delay when red flags |
Pharmacology
Medication | Mechanism | Onset | Role in Therapy | Limitations |
Methylprednisolone 60 mg IV daily | Glucocorticoid | Hours | First‑line | Hyperglycemia, infection |
Infliximab (rescue) | Anti‑TNF | Hours–days | Steroid‑refractory | TB/hep B screen |
Cyclosporine (alternative) | Calcineurin inhibitor | Hours–days | Rescue option | Nephrotoxicity |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy
Patient Education / Counseling
- Explain red flags, adherence, and follow‑up plan
References
- ECCO UC Therapeutics (2022/2023) — Link
- AGA Moderate-to-Severe UC Guideline (2020) — Link